Severe hypomagnesemia is a serious clinical condition. Proton pump inhibitor (PPI) induced hypomagnesemia has been recognized since 2006. In March 2011 the U.S. Food and Drug Administration advised that long-term use of PPI can induce hypomagnesemia. We report the first Japanese case of hypomagnesemia associated with chronic use of PPIs in a 64-year-old man hospitalized for nausea, bilateral ankle arthritis, and tremor of the extremities who had convulsions 3 days after admission. Blood analysis showed severe hypomagnesemia. He had been taking rabeprazole (10 mg/day) for 5 years. After stopping rabeprazole and correcting the electrolytes imbalances, his symptoms improved without recurrence.
Introduction
Magnesium is implicated in many biochemical and physiological processes in our bodies as an essential cation. Hypomagnesemia may arise from various disorders, and can cause tetany, convulsions, cardiac arrhythemias, hypocalcemia, and hypokalemia.
PPI is among the most widely used drug for the treatment and prevention of dyspeptic symptoms, gastritis and esophagitis (1) . In general, PPIs are well tolerated. PPI-induced hypomagnesemia has been recognized since 2006 (2) . Very few cases of hypomagnesemia related to long term use of PPI have been published (2, 3) . In March 2011 the U.S. Food and Drug Administration advised that long-term use of PPI can induce hypomagnesemia (4) . There have been no reports in Japan to date. Here, we now report the first Japanese case of hypomagnesemia associated with PPIs. Moderate edema was seen in both ankle joints, and the joints were painful. But no other abnormality was observed by routine physical examination.
Results of routine laboratory tests on the first visit showed hypokalemia, and the level of CRP was high. Serum magnesium and calcium levels were not examined ( Table 1 ). An electrocardiogram showed sinus rhythm. The findings of brain computed tomography were negative. Abdominal computed tomography only showed wall thickening in the sigmoid colon. After admission, he underwent colonoscopy and sigmoid colon cancer was found.
The orthopedist diagnosed that arthritis of both ankles and low grade fever was caused by pseudogout. Three days after admission, he had convulsions. Blood analysis showed severe hypomagnesemia (0.2 mg/dL), hypocalcemia (5.8 mg/ dL), and hypokalemia (2.3 mEq/L) ( Table 2 ). The levels of serum renin and aldosterone were normal. He received supplementation with intravenous calcium, potassium, and magnesium. Rabeprazole was discountinued ( Figure) . In 7 days, the levels of serum calcium, potassium, and magnesium had normalized and his symptoms were resolved. Since the discontinuation of PPI, his serum magnesium level has remained normal to the present time.
Discussion
Magnesium is the second most abundant intracellular cation in the organism. Its functions include regulation of enzymatic activity, ion transport, membrane stabilization, and nerve conduction (5) . It is of particular importance in energy metabolism since all enzymatic reactions involving ATP have an absolute requirement for magnesium. The serum magnesium level represents only 0.5% of total body magnesium stores, and its normal range is from 1.9-3.1 mg/dL. Fluctuations in serum magnesium levels depend largely on the balance between intestinal absorption and renal excretion.
Symptoms attributable to hypomagnesemia do not occur until plasma concentrations are lower than 1.2 mg/dL (6).
The symptoms of magnesium deficiency relate to the central role of magnesium in ATP metabolism and neuromuscular transmission. Symptoms can include tremor, muscle cramps, seizures, anorexia, nausea, cardiac conduction disturbances, and arrhythmias (2, 3, 7-10). Jones et al. (11) have reported hypomagnesemia related to pseudogout. Severely hypomagnesemic patients have coexistent hypokalemia and hypocalcemia. Potassium is lost from cells into the extracellular fluid and then into the urine because magnesium deficiency impairs the renal conservation of potassium. Hypocalcemia develops with prolonged, and severe hypomagnesemia, principally because of impaired PTH secretion.
Common causes of acquired hypomagnesemia are diarrhea, malabsorption syndromes, small bowel bypass surgery, primary aldosteronism, and heavy alcohol consumption, in addition to drugs such as loop diuretics, thiazide-type diuretics, aminoglycosides, cisplatin, Amphotericin B, and cyclosporine. Hypomagnesemia associated with PPIs was first described by Epstein et al. (2) in 2006. Fewer than 30 cases have been described. The mean period from the start of PPI to the occurrence of hypommagnesemia is not clear. A few patients had used PPIs for only 1-2 years, but most cases were associated with long-term PPI use; patients had received PPIs for 5 or more years (6) . Not only rabeprazol but also omeprazole, esomeprazole, pantoprazole, and lansoprazole have been implicated (12) .
The morbidity of PPI-induced hypomagnesemia is not clear. Furlanetto and Faulhaber (13) reported an asymptomatic case of hypomagnesemia associated with the chronic use of PPI. Mild hypomagnesemia is often asymptomatic. Hypomagnsemia may be underdiagnosed because of the low frequency of monitoring magesium levels in routine clinical practice (14, 15) . The monitoring of serum magnesium levels should be considered in patients with chronic use of PPIs.
The mechanism of PPI-induced hypomagnesemia is not clear. Renal magnesium wasting in patients with PPIinduced hypomagnesemia has not been identified. This suggests that the problem lies with the gastrointestinal system. Magnesium is absorbed in the small intestine through active and passive transport systems. An active transcellular process mediated by transport proteins TRPM6 and TRPM7 are normally responsible for approximately 30% of the absorption, while a passive paracellular pathway through enterocyte tight junction is responsible for the remaining 70% (6, 16) . Kuipers et al. (3) suggested that the function of the TRPM 6 and TRPM7 channels might be impaired by the lack of protons or that the affected patients are heterozygous for mutations in the TRPM6 genes (17) . Another possibility is that the passive paracellular transport mechanism is much less efficient. Evenpoel demonstrated that esomeprazole can increase the inward intestinal permeability to sucrose, suggesting that the function of the tight junction barrier that controls paracellular transport can be affected by PPIs (18) . However, that hypothesis remains unproven. The treatment of patients with hypomagnesemia associated with PPIs is magnesium supplementation and discontinuation of the PPI. To stop the PPI is the most important treatment. Shabajee et al. (8) reported a case where, despite supplementation, hypomagnesemia persisted for 21 months. In that case, the serum magnesium returned to normal within 1-2 weeks after PPI therapy was discontinued. Epstein et al. (2) reported the recurrence of hypomagnesemia following reintroduction of another PPI within 2 weeks. PPIs should be replaced by histamine 2 receptor antagonists such as ranitidine or cimetidine for patients with symptomatic hypomagnesaemia associated with PPIs (9).
In conclusion, this is the first Japanese case report of hypomagnesemia associated with PPIs. PPIs are currently widely used for many clinical situations. Hypomagnesemia associated with PPIs is very rare, but it is potentially life threatening. This adverse effect might be underdiagnosed because of a lack of knowledge and the low frequency of monitoring magnesium level in routine clinical practice. Magnesium loss in patients with long-term use of PPIs should be considered in the differential diagnosis of hypomagnesemia, hypokalemia and hypocalcemia at any age, and monitoring magnesium levels should be considered in patients treated chronically with PPIs.
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